These side effects may include: pain, redness and swelling at the injection site, axillary (or groin) swelling or tenderness, fatigue, headache, muscle pain, chills, joint pain, and fever. However, they are mild or moderate and transient, resolving within a few days. Some side effects are reported to be very common (defined as 10% or more) among recipients of all vaccines.Refer to Preparations authorized for use in Canada for more information. The XBB.1.5 vaccines are now the recommended products. These include messenger ribonucleic acid (mRNA) vaccines (preferred) and a protein subunit vaccine. Several vaccines for COVID-19 are authorized and available for use in Canada.However, some populations are at increased risk of exposure to the virus due to living or occupational settings and some populations are at increased risk of severe outcomes due to biological and/or social factors. Anyone can be infected with SARS-CoV-2.Novel coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Key information (refer to text and tables for details) What Blood products, human immunoglobulin and timing of immunization.Tuberculin skin testing (TST) and interferon gamma release assay (IGRA).Guidance on reporting adverse events following immunization (AEFI).Uncommon, rare and very rare adverse events.Concurrent administration with other vaccines.Overview of authorized mRNA XBB.1.5 vaccines by product and age Dose and route of administration of available products.Individuals previously infected with SARS-CoV-2.Pregnancy registry information by vaccine product Summary of number of recommended XBB.1.5 mRNA COVID-19 vaccine doses based on previous non-XBB.1.5 vaccination history Immunization schedule for previously unvaccinated individuals by age starting their vaccinations with XBB.1.5 mRNA COVID-19 vaccines Immunogenicity, efficacy and effectiveness.Preparations authorized for use in Canada.This information is captured in the table of updates. This chapter was updated to further reflect the authorization of Novavax Nuvaxovid XBB.1.5 vaccine. Last partial content update: December 15, 2023
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |